The U.S. reported its first human death from the H5 bird flu strain this week, causing a spike in vaccine developer stocksModerna(NASDAQ:MRNA),Novavax(NASDAQ:NVAX),CureVac(NASDAQ:CVAC) andPfizer(NYSE:PFE).

Vaccine production efforts are ramping up as health officials monitor the outbreak closely. In an update on Monday, CDC said there have been 66 confirmed cases in the U.S. in the 2024 outbreak.

CDC said the public risk remains low. Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.

Vaccine Providers in the Limelight

In the...